Literature DB >> 26918916

APOBEC3A damages the cellular genome during DNA replication.

Abby M Green1,2, Sébastien Landry3, Konstantin Budagyan4, Daphne C Avgousti4, Sophia Shalhout5, Ashok S Bhagwat5,6, Matthew D Weitzman2,4.   

Abstract

The human APOBEC3 family of DNA-cytosine deaminases comprises 7 members (A3A-A3H) that act on single-stranded DNA (ssDNA). The APOBEC3 proteins function within the innate immune system by mutating DNA of viral genomes and retroelements to restrict infection and retrotransposition. Recent evidence suggests that APOBEC3 enzymes can also cause damage to the cellular genome. Mutational patterns consistent with APOBEC3 activity have been identified by bioinformatic analysis of tumor genome sequences. These mutational signatures include clusters of base substitutions that are proposed to occur due to APOBEC3 deamination. It has been suggested that transiently exposed ssDNA segments provide substrate for APOBEC3 deamination leading to mutation signatures within the genome. However, the mechanisms that produce single-stranded substrates for APOBEC3 deamination in mammalian cells have not been demonstrated. We investigated ssDNA at replication forks as a substrate for APOBEC3 deamination. We found that APOBEC3A (A3A) expression leads to DNA damage in replicating cells but this is reduced in quiescent cells. Upon A3A expression, cycling cells activate the DNA replication checkpoint and undergo cell cycle arrest. Additionally, we find that replication stress leaves cells vulnerable to A3A-induced DNA damage. We propose a model to explain A3A-induced damage to the cellular genome in which cytosine deamination at replication forks and other ssDNA substrates results in mutations and DNA breaks. This model highlights the risk of mutagenesis by A3A expression in replicating progenitor cells, and supports the emerging hypothesis that APOBEC3 enzymes contribute to genome instability in human tumors.

Entities:  

Keywords:  APOBEC3; ATR kinase; DNA replication; DNA replication stress; cell cycle checkpoint; cytosine deamination; single-stranded DNA

Mesh:

Substances:

Year:  2016        PMID: 26918916      PMCID: PMC4889253          DOI: 10.1080/15384101.2016.1152426

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  69 in total

1.  An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.

Authors:  Adam Jarmuz; Ann Chester; Jayne Bayliss; Jane Gisbourne; Ian Dunham; James Scott; Naveenan Navaratnam
Journal:  Genomics       Date:  2002-03       Impact factor: 5.736

Review 2.  Cell-cycle checkpoints and cancer.

Authors:  Michael B Kastan; Jiri Bartek
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

3.  Strand-biased cytosine deamination at the replication fork causes cytosine to thymine mutations in Escherichia coli.

Authors:  Ashok S Bhagwat; Weilong Hao; Jesse P Townes; Heewook Lee; Haixu Tang; Patricia L Foster
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-02       Impact factor: 11.205

4.  A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression.

Authors:  Kum-Joo Shin; Estelle A Wall; Joelle R Zavzavadjian; Leah A Santat; Jamie Liu; Jong-Ik Hwang; Robert Rebres; Tamara Roach; William Seaman; Melvin I Simon; Iain D C Fraser
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-31       Impact factor: 11.205

Review 5.  APOBECs and virus restriction.

Authors:  Reuben S Harris; Jaquelin P Dudley
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

Review 6.  Base excision repair.

Authors:  Hans E Krokan; Magnar Bjørås
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-04-01       Impact factor: 10.005

7.  Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair.

Authors:  Eva Petermann; Manuel Luís Orta; Natalia Issaeva; Niklas Schultz; Thomas Helleday
Journal:  Mol Cell       Date:  2010-02-26       Impact factor: 17.970

8.  APOBEC3B is an enzymatic source of mutation in breast cancer.

Authors:  Michael B Burns; Lela Lackey; Michael A Carpenter; Anurag Rathore; Allison M Land; Brandon Leonard; Eric W Refsland; Delshanee Kotandeniya; Natalia Tretyakova; Jason B Nikas; Douglas Yee; Nuri A Temiz; Duncan E Donohue; Rebecca M McDougle; William L Brown; Emily K Law; Reuben S Harris
Journal:  Nature       Date:  2013-02-06       Impact factor: 49.962

9.  Analysis of the functions of herpes simplex virus type 1 regulatory protein ICP0 that are critical for lytic infection and derepression of quiescent viral genomes.

Authors:  Roger D Everett; Marie-Laure Parsy; Anne Orr
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

10.  Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair.

Authors:  Nicholas J Haradhvala; Paz Polak; Petar Stojanov; Kyle R Covington; Eve Shinbrot; Julian M Hess; Esther Rheinbay; Jaegil Kim; Yosef E Maruvka; Lior Z Braunstein; Atanas Kamburov; Philip C Hanawalt; David A Wheeler; Amnon Koren; Michael S Lawrence; Gad Getz
Journal:  Cell       Date:  2016-01-21       Impact factor: 41.582

View more
  32 in total

1.  Avoidance of APOBEC3B-induced mutation by error-free lesion bypass.

Authors:  James I Hoopes; Amber L Hughes; Lauren A Hobson; Luis M Cortez; Alexander J Brown; Steven A Roberts
Journal:  Nucleic Acids Res       Date:  2017-05-19       Impact factor: 16.971

2.  Mechanisms for targeted, purposeful mutation revealed in an APOBEC-DNA complex.

Authors:  Emily K Schutsky; Zachary M Hostetler; Rahul M Kohli
Journal:  Nat Struct Mol Biol       Date:  2017-02-06       Impact factor: 15.369

Review 3.  The spectrum of APOBEC3 activity: From anti-viral agents to anti-cancer opportunities.

Authors:  Abby M Green; Matthew D Weitzman
Journal:  DNA Repair (Amst)       Date:  2019-09-13

Review 4.  Functions and Malfunctions of Mammalian DNA-Cytosine Deaminases.

Authors:  Sachini U Siriwardena; Kang Chen; Ashok S Bhagwat
Journal:  Chem Rev       Date:  2016-09-01       Impact factor: 60.622

5.  APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.

Authors:  Rémi Buisson; Michael S Lawrence; Cyril H Benes; Lee Zou
Journal:  Cancer Res       Date:  2017-07-11       Impact factor: 12.701

6.  Activation of DNA damage repair factors in HPV positive oropharyngeal cancers.

Authors:  Takeyuki Kono; Paul Hoover; Kate Poropatich; Tatjana Paunesku; Bharat B Mittal; Sandeep Samant; Laimonis A Laimins
Journal:  Virology       Date:  2020-05-22       Impact factor: 3.616

7.  Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.

Authors:  Abby M Green; Konstantin Budagyan; Katharina E Hayer; Morgann A Reed; Milan R Savani; Gerald B Wertheim; Matthew D Weitzman
Journal:  Cancer Res       Date:  2017-06-27       Impact factor: 12.701

8.  APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis.

Authors:  Sonja M Wörmann; Amy Zhang; Fredrik I Thege; Robert W Cowan; Dhwani N Rupani; Runsheng Wang; Sara L Manning; Chris Gates; Weisheng Wu; Rena Levin-Klein; Kimal I Rajapakshe; Meifang Yu; Asha S Multani; Ya'an Kang; Cullen M Taniguchi; Katharina Schlacher; Melena D Bellin; Matthew H G Katz; Michael P Kim; Jason B Fleming; Steven Gallinger; Ravikanth Maddipati; Reuben S Harris; Faiyaz Notta; Susan R Ross; Anirban Maitra; Andrew D Rhim
Journal:  Nat Cancer       Date:  2021-11-18

Review 9.  Molecular origins of APOBEC-associated mutations in cancer.

Authors:  Mia Petljak; John Maciejowski
Journal:  DNA Repair (Amst)       Date:  2020-07-06

10.  Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner.

Authors:  Kailiang Zhao; Qiang Zhang; Sheryl A Flanagan; Xueting Lang; Long Jiang; Leslie A Parsels; Joshua D Parsels; Weiping Zou; Theodore S Lawrence; Rémi Buisson; Michael D Green; Meredith A Morgan
Journal:  Mol Cancer Res       Date:  2021-05-27       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.